Nuclear Medicine and Biology
Volume 34, Issue 5 , Pages 479-482 , July 2007

Anesthesia increases in vivo N-([18F]fluoroethyl)piperidinyl benzilate binding to the muscarinic cholinergic receptor

Received 16 March 2007 ,Accepted 14 April 2007.

References 

  1. Ginovart N, Hassoun W, Le Cavorsin M, Veyre L, Le Bars D, Leveil V. Effects of amphetamine and evoked dopamine release on [11C]raclopride binding in anesthetized cats. Neuropsychopharmacology. 2002;27:72–84
  2. Hassoun W, Le Cavorsin M, Ginovart N, Zimmer L, Gualda V, Bonnefoi F, et al. PET study of the [11C]raclopride binding in the striatum of the awake cat: effects of anaesthetics and role of cerebral blood flow. Eur J Nucl Med. 2003;30:141–148
  3. Itoh T, Tanaka M, Kobayashi K, Suzuki K, Inoue O. Binding kinetics of 11C-N-methyl piperidinyl benzilate (11C-NMPB) in a rhesus monkey using the cerebellum as a reference region. Ann Nucl Med. 2005;19:499–505
  4. Kobayashi K, Inoue O, Watanabe Y, Onoe H, Langstrom B. Difference in response of D2 receptor between 11C-N-methylspiperone and 11C-raclopride against anesthetics in rhesus monkey brain. J Neural Trans. 1995;100:147–151
  5. Momosaki S, Hatano K, Kawasumi Y, Kato T, Hosol R, Kobayashi K, et al. Rat-PET study without anesthesia: anesthetics modify the dopamine D1 receptor binding in rat brain. Synapse. 2004;54:207–213
  6. Tsukada H, Nishiyama S, Kakiuchi T, Ohba H, Sato K, Harada N. Ketamine alters the availability of striatal dopamine transporter as measured by [11C]beta-CFT and [11C]beta-CFT-FE in the monkey brain. Synapse. 2001;42:273–280
  7. Votaw JR, Byas-Smith MG, Voll R, Halkar R, Goodman MM. Isoflurane alters the amount of dopamine transporter expressed on the plasma membrane in humans. Anethesiology. 2004;101:1128–1135
  8. Skaddan MB, Jewett DM, Sherman PS, Kilbourn MR. (R)-N-[11C]Methyl-3-pyrrolidinyl benzilate, a high affinity reversible radioligand for PET studies of the muscarinic acetylcholine receptor. Synapse. 2002;45:31–37
  9. Skaddan MB, Kilbourn MR, Snyder SE, Sherman PS. Acetylcholinesterase inhibition increases in vivo N-(2-[18F]fluoroethyl)-4-piperidyl benzilate binding to muscarinic acetylcholine receptors. J Cereb Blood Flow Metab. 2001;21:144–148
  10. Ma B, Sherman PS, Moskwa JE, Koeppe RA, Kilbourn MR. Sensitivity of [11C]N-methylpyrollidinyl benzilate ([11C]NMPYB) to endogenous acetylcholine: PET imaging vs. tissue sampling methods. Nucl Med Biol. 2004;31:393–397
  11. Mulholland GK, Kilbourn MR, Sherman P, Carey JE, Frey KA, Koeppe RA, et al. Synthesis, in vivo biodistribution and dosimetry of [11C]N-methylpiperidyl benzilate ([11C]NMPB), a muscarinic acetylcholine receptor antagonist. Nucl Med Biol. 1995;22:13–17
  12. Skaddan MB, Kilbourn MR, Snyder SE, Sherman PS, Desmond TJ, Frey KA. Synthesis, radiolabeling, and biological evaluation of piperidyl and pyrrolidyl benzilates as in vivo ligands for the muscarinic acetylcholine receptors. J Med Chem. 2000;43:4552–4562
  13. Kilbourn M, Sherman P. In vivo binding of (+)-α-[3H]dihydrotetrabenazine to the vesicular monoamine transporter of rat brain: bolus vs. equilibrium studies. Eur J Pharm. 1997;331:161–168
  14. Tsukada H, Nishiyama S, Fukumoto D, Ohba H, Sato K, Kakiuchi T. Effects of acute acetylcholinesterase inhibition on the cerebral cholinergic neuronal system and cognitive function: functional imaging of the conscious monkey brain using animal PET in combination with microdialysis. Synapse. 2004;52:1–10
  15. Kilbourn MR, Nguyen TB, Snyder SE, Koeppe RA. One for all or one for each matching radiotracers and brain pharmacokinetics. In:  Carson RE,  Daube-Witherspoon ME,  Herscovitch P editor. Quantitative functional brain imaging with positron emission tomography. San Diego: Academic Press; 1998;p. 261–265

PII: S0969-8051(07)00121-7

doi: 10.1016/j.nucmedbio.2007.04.008

Nuclear Medicine and Biology
Volume 34, Issue 5 , Pages 479-482 , July 2007

Article Tools